DK3903772T3 - Sammensætninger indeholdende en opioid vækstfaktorreceptor (ogfr)-antagonist til brug i fremme af knogledannelse og i behandling af kræft - Google Patents

Sammensætninger indeholdende en opioid vækstfaktorreceptor (ogfr)-antagonist til brug i fremme af knogledannelse og i behandling af kræft

Info

Publication number
DK3903772T3
DK3903772T3 DK21170355.8T DK21170355T DK3903772T3 DK 3903772 T3 DK3903772 T3 DK 3903772T3 DK 21170355 T DK21170355 T DK 21170355T DK 3903772 T3 DK3903772 T3 DK 3903772T3
Authority
DK
Denmark
Prior art keywords
ogfr
antagonist
growth factor
compositions containing
treating cancer
Prior art date
Application number
DK21170355.8T
Other languages
English (en)
Inventor
Nikhil A Thakur
Bryan S Margulies
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Application granted granted Critical
Publication of DK3903772T3 publication Critical patent/DK3903772T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
DK21170355.8T 2014-05-30 2015-05-28 Sammensætninger indeholdende en opioid vækstfaktorreceptor (ogfr)-antagonist til brug i fremme af knogledannelse og i behandling af kræft DK3903772T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005359P 2014-05-30 2014-05-30
EP15799544.0A EP3148517B1 (en) 2014-05-30 2015-05-28 Compositions and methods to promote bone formation

Publications (1)

Publication Number Publication Date
DK3903772T3 true DK3903772T3 (da) 2025-09-01

Family

ID=54699759

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15799544.0T DK3148517T3 (da) 2014-05-30 2015-05-28 Sammensætninger og fremgangsmåder til fremme af knogledannelse
DK21170355.8T DK3903772T3 (da) 2014-05-30 2015-05-28 Sammensætninger indeholdende en opioid vækstfaktorreceptor (ogfr)-antagonist til brug i fremme af knogledannelse og i behandling af kræft

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15799544.0T DK3148517T3 (da) 2014-05-30 2015-05-28 Sammensætninger og fremgangsmåder til fremme af knogledannelse

Country Status (12)

Country Link
US (2) US10208306B2 (da)
EP (2) EP3148517B1 (da)
JP (2) JP6920196B2 (da)
CN (2) CN116059376A (da)
AU (3) AU2015267006B2 (da)
CA (1) CA2984889C (da)
DK (2) DK3148517T3 (da)
ES (2) ES3041577T3 (da)
HU (1) HUE055062T2 (da)
PL (1) PL3148517T3 (da)
PT (1) PT3148517T (da)
WO (1) WO2015184059A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116059376A (zh) * 2014-05-30 2023-05-05 纽约州立大学研究基金会 促进骨形成的组合物和方法
CN109432504B (zh) * 2018-11-27 2021-11-16 中国人民解放军总医院第四医学中心 一种成骨基因干预功能材料及其制备方法
JP2022541452A (ja) * 2019-07-15 2022-09-26 ロバクサ がんの治療のための方法および組成物
JP7551339B2 (ja) * 2020-06-04 2024-09-17 株式会社三共 遊技機
JP7551341B2 (ja) * 2020-06-04 2024-09-17 株式会社三共 遊技機
IL299913A (en) * 2020-07-17 2023-03-01 Zetagen Therapeutics Inc Methods and preparations for bone grafting using iron auxiliary materials
WO2023150305A1 (en) * 2022-02-04 2023-08-10 Kim Seong Jin Method of making bone and cartilage
US20250049784A1 (en) * 2023-08-07 2025-02-13 Zetagen Therapeutics, Inc. Methods of treating prostate cancer or metastasized prostate cancer
US11957676B1 (en) * 2023-08-07 2024-04-16 Zetagen Therapeutics, Inc. Controlled release formulation and minimally invasive method of administration to locally treat cancer
US12403118B1 (en) 2025-03-05 2025-09-02 Zetagen Therapeutics, Inc. Cancer treatments using modified fatty acids and the carriers to administer them
CN120209114B (zh) * 2025-03-07 2026-04-07 首都医科大学 一种含有penk蛋白的组合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882944A (en) 1993-06-23 1999-03-16 The Regents Of The University Of California Methods for G protein coupled receptor activity screening
US6007986A (en) 1993-06-23 1999-12-28 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic activity screening
US6270979B1 (en) 1993-06-23 2001-08-07 The Regents Of The University Of California Methods for anti-addictive narcotic analgesic treatments
AU2810497A (en) * 1996-04-19 1997-11-12 University Of Washington Methods for inducing bone formation
DE60119696T2 (de) 2000-03-15 2007-01-25 Wolfgang Ross Sadee Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
WO2002006373A1 (en) * 2000-07-17 2002-01-24 University Of Utah Research Foundation Hydrogel films and methods of making and using therefor
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20070197573A1 (en) * 2005-10-04 2007-08-23 Wolfgang Sadee Compositions and methods in the treatment of bone metabolic disorders
GB2463474B (en) 2008-09-11 2012-05-02 Agency Science Tech & Res Therapeutic bone growth and regeneration
WO2010111278A1 (en) * 2009-03-23 2010-09-30 The Texas A&M University System Compositions of mesenchymal stem cells to regenerate bone
US8529933B2 (en) * 2009-07-27 2013-09-10 Warsaw Orthopedic, Inc. Biphasic calcium phosphate cement for drug delivery
EP2793961A4 (en) * 2011-12-23 2015-06-24 Skeletal Kinetics Llc Porous calcium phosphate granule and process for its preparation and use
CN116059376A (zh) * 2014-05-30 2023-05-05 纽约州立大学研究基金会 促进骨形成的组合物和方法

Also Published As

Publication number Publication date
HUE055062T2 (hu) 2021-10-28
AU2020204496B2 (en) 2022-03-31
US20150344882A1 (en) 2015-12-03
ES3041577T3 (en) 2025-11-13
CA2984889C (en) 2024-01-02
EP3903772A1 (en) 2021-11-03
CN116059376A (zh) 2023-05-05
PT3148517T (pt) 2021-07-23
AU2022203758B2 (en) 2024-02-15
CA2984889A1 (en) 2015-12-03
EP3903772B1 (en) 2025-08-06
AU2015267006A1 (en) 2016-12-08
JP6920196B2 (ja) 2021-08-18
JP2020097619A (ja) 2020-06-25
CN106535880A (zh) 2017-03-22
EP3148517A4 (en) 2017-05-17
AU2022203758A1 (en) 2022-06-23
EP3148517B1 (en) 2021-04-28
US10208306B2 (en) 2019-02-19
WO2015184059A1 (en) 2015-12-03
PL3148517T3 (pl) 2021-11-29
JP6916918B2 (ja) 2021-08-11
US20190093109A1 (en) 2019-03-28
US12258561B2 (en) 2025-03-25
JP2017518369A (ja) 2017-07-06
AU2015267006B2 (en) 2020-04-09
EP3148517A1 (en) 2017-04-05
DK3148517T3 (da) 2021-07-26
AU2020204496A1 (en) 2020-07-23
ES2881626T3 (es) 2021-11-30

Similar Documents

Publication Publication Date Title
DK3903772T3 (da) Sammensætninger indeholdende en opioid vækstfaktorreceptor (ogfr)-antagonist til brug i fremme af knogledannelse og i behandling af kræft
IL276314A (en) Preparations for the treatment of cancer using PD-1 axis binding antagonists and MEK inhibitors
IL283429A (en) Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
IL246680A0 (en) Materials and preparations for the treatment of her2-positive tumors
DK3157629T3 (da) Fremgangsmåder til cancerbehandling med antagonister mod pd-1 og pd-l1 i kombination med strålebehandling
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
DK3245225T3 (da) Sammensætninger og fremgangsmåder til behandling og detektering af cancere
PL3806898T3 (pl) Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
SI3594238T1 (sl) Sestavki protiteles za zdravljenje tumorja
ZA201801024B (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
DK3177608T3 (da) Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
NZ767823A (en) Processes and intermediates in the preparation of c5ar antagonists
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
ZA201703443B (en) Oral rehydration composition and methods thereof
PT3223906T (pt) Métodos e composições para potencializar a ação de analgésicos de opioides usando alcaloides de iboga
IL290004A (en) Pharmaceutical preparations containing cis-clomiphene for use in the method of treating the loss of bone density
PT2976150T (pt) Dispositivo para misturar e distribuir cimento ósseo
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER
DK3251699T3 (da) Sammensætning omfattende methylphenidat og ondansetron til anvendelse i stofrelaterede forstyrrelser
HRP20182033T8 (hr) Uređaj u obliku kompleta za miješanje i injiciranje koštanog cementa
ZA201605109B (en) Compositions and methods for treating neutropenia
IT201700037319A1 (it) Composizione naturale per uso in ginecologia
DK3359209T3 (en) Compositions and methods for treatment of bone defects
PL3262069T3 (pl) Zastosowanie przeciwciał i antagonistów skierowanych przeciwko LRG1 w leczeniu
EP3328495A4 (en) METHOD AND COMPOSITIONS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS